BICX
BioCorRx Inc.0.3400
-0.0360-9.57%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.05MP/E (TTM)
-Basic EPS (TTM)
-0.32Dividend Yield
0%Recent Filings
10-K
10-Q
Q3 FY2025 results
BioCorRx posted Q3 revenue of $635K from new Lucemyra supply/distribution sales (100% y/y growth), yet posted an operating loss of $1.9M amid $1.0M R&D spend and $359K implant costs from the March 2025 asset purchase. Grant income hit $867K while net loss attributable to common narrowed to $1.9M or $(0.11)/share from $(0.14) y/y, reconciling to 18.2M diluted shares. Cash climbed to $288K on $1.7M YTD financing inflows exceeding $1.5M operating burn; total debt ~$2.5M with related-party notes. Lucemyra deal added $2.8M goodwill, $452K indefinite trademark, and $2.7M customer base (10-year life). Revenue stays 95% tied to one customer.
10-Q
Q2 FY2025 results
BioCorRx revenue jumped to $178K in Q2 FY2025 ended June 30 (up 4,306% y/y, 44% q/q derived), driven by $176K supply and distribution sales from the Lucemyra asset purchase closed March 4, 2025 for $828K total consideration (stock/warrants/contingent), recognizing $2.8M goodwill and $2.7M customer base intangibles (10-year life). Operating loss widened slightly to $1.4M while net loss held at $(1.4M) versus $(1.2M) y/y, with interest down sharply yet offset by $55K debt settlements. Cash ticked to $112K on $840K related-party notes, operating cash burn $816K; free cash flow not disclosed in the 10-Q. Revenue hinges on two customers.
8-K
Securities deal signed
BioCorRx entered a securities purchase agreement on July 29, 2025, with accredited investors for $350,000, issuing 1,000,000 shares and warrants for another 1,000,000 shares at $0.35 exercise price, exercisable five years. Deal splits into two tranches; second optional within 60 days post-due diligence. Transaction awaits closing. Investors gain board seat, observer rights, and pro rata protections post-second tranche.
10-Q
Q1 FY2025 results
BioCorRx posted Q1 revenue of $134,899, up sharply from $3,620 y/y, all from new Lucemyra supply and distribution sales after the March 4, 2025 asset purchase from USWM, LLC—closed for $392K upfront (contingent), $153.5K stock, $89.8K warrants, recognizing $2.8M goodwill and $2.7M customer base intangibles (10-year life). Operating loss narrowed to $938K from $969K y/y while net loss improved to $852K from $1.2M, thanks to $414K grant income versus $113K, though debt settlements added $133K hit and interest fell on conversions. Cash dipped to $24K after $690K operating burn, offset by $626K related-party notes; total debt ~$2.5M with $13M current liabilities. Revenue hinges on two customers.
ACHC
Acadia Healthcare Company, Inc.
14.43+0.21
BBNX
Beta Bionics, Inc.
29.63-0.09
BRGX
BioRegenx, Inc
0.02+0.00
BSX
Boston Scientific Corporation
92.95+0.76
BTMD
Biote Corp.
2.67+0.05
CRMD
CorMedix Inc.
11.44+0.11
FCHS
First Choice Healthcare Solutio
0.01+0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NUTX
Nutex Health Inc.
171.72-4.06
SRXH
SRX Health Solutions, Inc.
0.38+0.07